Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of intralesional corticosteroid application for hemangiomas.
Turk J Med Sci 2015; 45(2):335-8TJ

Abstract

BACKGROUND/AIM

There are different modalities for management of infantile hemangiomas (IHs). In this report, our aim is to evaluate whether intralesional corticosteroid treatment is associated with systemic side effects and whether this is an effective treatment modality for IH.

MATERIALS AND METHODS

Six children treated with intralesional corticosteroids for problematic hemangiomas were included in the study. Clinical characteristics, response to treatment, weight, height, blood pressure, morning serum cortisol, and adrenocorticotropic hormone levels were recorded.

RESULTS

Each child received intralesional triamcinolone at a dose of 2 mg/kg for 2-5 injections at monthly intervals. Subjects were followed for 1 year. All patients had adrenal suppression following the second or third triamcinolone injections. Five patients demonstrated partial response and one demonstrated no response.

CONCLUSION

Intralesional steroid injection may effectively induce the resolution of hemangiomas, but all the patients in our group had adrenal suppression after treatment. The use of intralesional steroid therapy is not a superior treatment option for hemangiomas. It also has side effects comparable to systemic steroids.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26084124

Citation

Emir, Suna, et al. "Efficacy and Safety of Intralesional Corticosteroid Application for Hemangiomas." Turkish Journal of Medical Sciences, vol. 45, no. 2, 2015, pp. 335-8.
Emir S, Gürlek Gökçebay D, Demirel F, et al. Efficacy and safety of intralesional corticosteroid application for hemangiomas. Turk J Med Sci. 2015;45(2):335-8.
Emir, S., Gürlek Gökçebay, D., Demirel, F., & Tunç, B. (2015). Efficacy and safety of intralesional corticosteroid application for hemangiomas. Turkish Journal of Medical Sciences, 45(2), pp. 335-8.
Emir S, et al. Efficacy and Safety of Intralesional Corticosteroid Application for Hemangiomas. Turk J Med Sci. 2015;45(2):335-8. PubMed PMID: 26084124.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of intralesional corticosteroid application for hemangiomas. AU - Emir,Suna, AU - Gürlek Gökçebay,Dilek, AU - Demirel,Fatma, AU - Tunç,Bahattin, PY - 2015/6/19/entrez PY - 2015/6/19/pubmed PY - 2015/7/15/medline SP - 335 EP - 8 JF - Turkish journal of medical sciences JO - Turk J Med Sci VL - 45 IS - 2 N2 - BACKGROUND/AIM: There are different modalities for management of infantile hemangiomas (IHs). In this report, our aim is to evaluate whether intralesional corticosteroid treatment is associated with systemic side effects and whether this is an effective treatment modality for IH. MATERIALS AND METHODS: Six children treated with intralesional corticosteroids for problematic hemangiomas were included in the study. Clinical characteristics, response to treatment, weight, height, blood pressure, morning serum cortisol, and adrenocorticotropic hormone levels were recorded. RESULTS: Each child received intralesional triamcinolone at a dose of 2 mg/kg for 2-5 injections at monthly intervals. Subjects were followed for 1 year. All patients had adrenal suppression following the second or third triamcinolone injections. Five patients demonstrated partial response and one demonstrated no response. CONCLUSION: Intralesional steroid injection may effectively induce the resolution of hemangiomas, but all the patients in our group had adrenal suppression after treatment. The use of intralesional steroid therapy is not a superior treatment option for hemangiomas. It also has side effects comparable to systemic steroids. SN - 1300-0144 UR - https://www.unboundmedicine.com/medline/citation/26084124/Efficacy_and_safety_of_intralesional_corticosteroid_application_for_hemangiomas_ L2 - https://medlineplus.gov/birthmarks.html DB - PRIME DP - Unbound Medicine ER -